Since TRAIL is an anti-inflammatory molecule, the high expression observed in RA patients with IHD could be the result of a compensatory mechanism to limit the potential pro-inflammatory effects triggered by other cytokines. This evidence concerns the gene TNFSF10 and rheumatoid arthritis.